BLPH — Bellerophon Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Bellerophon Says Q4 Loss Per Share $0.84
Brief: Bellerophon Therapeutics Announces First Patient Enrolled in Phase 3 REBUILD Study Evaluating INOpulse for the Treatment of Fibrotic Interstitial Lung Disease
Bellerophon drops as late-stage COVID-19 treatment trial put on hold
U.S. STOCKS ON THE MOVE-DPW, Ideanomics, Fuel Tech, Renren, oil and gas stocks
U.S. STOCKS ON THE MOVE-DPW, Fuel Tech, Ideanomics, Bellerophon, Niu Technologies
U.S. STOCKS ON THE MOVE-Ideanomics, DPW, Ashford Hospitality, SmileDirectClub
Brief: Bellerophon Therapeutics Q3 Loss Per Share $0.84
Brief: Bellerophon To Present Results From Its Phase 2 iNO-PF Study Of INOpulse® For The Treatment Of Fibrotic Interstitial Lung Disease At Upcoming Scientific Conferences
U.S. RESEARCH ROUNDUP-Esperion Therapeutics, Graco, Johnson Controls International Plc
Brief: Bellerophon Provides Clinical Program Update And Reports Second Quarter 2020 Financial Results
Brief: Bellerophon Enters Open Market Sale Agreement For An Aggregate Sales Price Of Up To $40 Mln
Brief: Bellerophon Therapeutics Announces Publication Of Cohort 1 Of Ino-Pf Phase 2/3 Study In The Chest Journal
Brief: Bellerophon Therapeutics Announces First Patient Treated In Phase 3 Clinical Study Of Inopulse® Inhaled Nitric Oxide Therapy For Covid-19
Brief: Bellerophon Therapeutics Added To Russell 3000® And Microcap® Indexes
Brief: Bellerophon Therapeutics Files For Mixed Shelf Of Up To $150 Million
Brief: Theodore Wang Reports 13.1% Stake In Bellerophon Therapeutics
U.S. STOCKS ON THE MOVE-Xenetic Biosciences, Dycom, Dynavax Technologies
Biotech blitz: Moderna, Bluebird lead $3 bln capital raise wave
Brief: Bellerophon Therapeutics Announces Pricing Of Public Offering Of Common Stock And Concurrent Registered Direct Offering